Market Place
Sourcing Support
Circle Pharma To Present At J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Circle Pharma Names CID-165 as Second Oncology Candidate
17 Dec 2025 //
BUSINESSWIRE
Circle Pharma Names Anne E. Borgman As Chief Medical Officer
01 Dec 2025 //
BUSINESSWIRE
Circle Pharma To Participate In Investor Conferences
04 Nov 2025 //
BUSINESSWIRE
Circle Pharma Appoints Rob Lauzen As Chief Financial Officer
03 Nov 2025 //
BUSINESSWIRE
Circle Pharma Reveals Cyclin D1 Program Preclinical Data
23 Oct 2025 //
BUSINESSWIRE
Circle Pharma to Present Cyclin D1 RxL Anti-Tumor Data at AACR
14 Oct 2025 //
BUSINESSWIRE
Circle Pharma Announces Presentation on Potential of CID-078
25 Sep 2025 //
BUSINESSWIRE
Circle Pharma & Eli Collaborate for AI-Driven Drug Discovery
09 Sep 2025 //
PRESS RELEASE
Circle Pharma`s Cyclin A/B Inhibition Shows Anti-Tumor Activity
20 Aug 2025 //
BUSINESSWIRE
Circle Pharma`s CID-078 Preclinical Data at Neuroblastoma Meeting
27 May 2025 //
BUSINESSWIRE
Circle Pharma to Present CID-078 Poster at ASCO 2025 Meeting
12 May 2025 //
BUSINESSWIRE
Circle Pharma to Share MoA Data on Cyclin A/B Inhibitors at AACR
22 Apr 2025 //
BUSINESSWIRE
Circle Pharma to Present at the Upcoming Investor Conferences
31 Mar 2025 //
BUSINESSWIRE
Circle Pharma Presents Preclinical Data on CID-078 at SABCS
09 Dec 2024 //
BUSINESSWIRE
Circle Pharma Highlights CID-078 Preclinical Data at EORTC
23 Oct 2024 //
BUSINESSWIRE
Circle Doses 1st Patients In Ph 1 Trial Of CID-078 for Tumors
15 Oct 2024 //
BUSINESSWIRE
Boehringer And Circle Pharma Collaborate On Novel Cancer Treatment
10 Oct 2024 //
BUSINESSWIRE
Circle Pharma Expands Leadership For Oral Macrocycle Therapies
16 Sep 2024 //
BUSINESSWIRE
Circle Pharma To Present CID-078 Data At World Lung Cancer Conference
09 Sep 2024 //
BUSINESSWIRE
Circle Pharma Closes $90M Series D to Advance Oral Macrocycle Therapies
03 Sep 2024 //
BUSINESSWIRE
Circle Pharma Files IND For Oral Cyclin A/B RxL Inhibitor
01 Jul 2024 //
BUSINESSWIRE
Compelling Data in Breast Cancer Treatment with Cyclin A/B Inhibitor Presented
23 Oct 2023 //
BUSINESSWIRE
Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC
09 Oct 2023 //
BUSINESSWIRE
Circle Pharma strengthens executive leadership team with two senior appointments
26 Jul 2023 //
BUSINESSWIRE
Circle’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors
19 Apr 2023 //
BUSINESSWIRE
Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
15 Dec 2022 //
BUSINESSWIRE
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer
26 Jul 2022 //
BUSINESSWIRE
Circle Pharma Announces Presentation at the AACR
11 Apr 2022 //
BUSINESSWIRE
Circle Pharma Appoints Evelyn Wang, PhD as its Vice President
12 Jul 2021 //
BUSINESSWIRE
Circle Pharma Raises $66 Million in Series C Financing
16 Jun 2021 //
BUSINESSWIRE
